曼恩凯德生物医疗（MNKD）在周三盘后交易中股价大涨6.49%，尽管公司公布的季度业绩略低于分析师预期。这一意外的股价上涨引起了投资者的广泛关注。
根据公司发布的财报，截至6月30日的季度，曼恩凯德实现收入7653万美元，同比增长5.7%，但略低于分析师预期的7860万美元。每股收益达到盈亏平衡点，高于去年同期的每股亏损1美分，但低于分析师平均预期的5美分。尽管业绩未达预期，但投资者似乎对公司的整体表现持乐观态度，特别是考虑到其收入的持续增长。
值得注意的是，尽管当前季度股价上涨，曼恩凯德今年迄今为止的股价仍下跌了37.9%。然而，分析师对该公司保持看好态度，平均评级为"买入"，12个月目标价中位数为9.00美元，较最近收盘价3.99美元高出约55.7%。这种乐观情绪可能是推动股价上涨的另一个因素，表明市场认为该公司仍有巨大的增长潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.